Back to search

Peptide record

TPDB22504

L17A/L21A L21A Antibacterial Anticancer Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB22504
L17A/L21A L21A
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF
standard
No
A 26-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.
Sequence
KWKSFLKTFKSAKKTVAHTAAKAISS
Physicochemical Analysis
C133H218N36O34
RNDCEQGMPY
K
2865.42
11.29
8
0
11
+7
3.07
-0.369
60.38
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
191.94
7
Residue Composition
number
5
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
1
I
1
L
7
K
0
M
2
F
0
P
4
S
3
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 5 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 1 L: 1 K: 7 M: 0 F: 2 P: 0 S: 4 T: 3 W: 1 Y: 0 V: 1
Chemical Descriptors
26
C133H218N36O34
2865.42
11.29
+7
3.07
-0.369
Free
L
Linear
Free
Anticancer
PeptideV13K
Evidence Records 18 records
Evidence 1 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=71 µMo/L
Anticancer
71 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 3 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 4 Activity

Activity

IC50
IC50=59.8 µMo/L
Anticancer
59.8 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 5 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 6 Activity

Activity

IC50
IC50=70.8 µMo/L
Anticancer
70.8 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 7 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Colorectal Cancer
SW-1116
Colon

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 8 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Colorectal Cancer
SW-1116
Colon

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 9 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Rhabdomyosarcoma Cancer
RD
Muscle

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 10 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Rhabdomyosarcoma Cancer
RD
Muscle

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 11 Activity

Activity

IC50
IC50=37.7 µMo/L
Anticancer
37.7 µM

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 12 Activity

Activity

IC50
IC50=15.6 µMo/L
Anticancer
15.6 µM

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 13 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Skin Cancer
B-16
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 14 Activity

Activity

IC50
IC50=63.5 µMo/L
Anticancer
63.5 µM

Target

Skin Cancer
B-16
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 15 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 16 Activity

Activity

IC50
IC50=64.7 µMo/L
Anticancer
64.7 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 17 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework. | Mol Cancer Ther | 2011
Evidence 18 Activity

Activity

MHC
Toxicity
334.4 µm
Hemolytic Cytotoxic
Hemolytic_activity: Human red blood cells: MHC>334.4 µmol/L | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Mol Cancer Ther. 2011 Mar 10(3):416-26.